Evidence map›Paper›PMID 31013810›Full record

ArticleCancers2019

Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR

Zhaorong Guo, Hiroshi Tada, Narufumi Kitamura, Yoh Hamada, Minoru Miyashita, Narumi Harada-Shoji, Akiko Sato, Yohei Hamanaka, Kouki Tsuboi, Nobuhisa Harada and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Zhaorong GuoDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. guozhaorong1@yahoo.co.jp.
Hiroshi TadaDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. hiroshi-tada@med.tohoku.ac.jp.
Narufumi KitamuraDepartment of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. n-kitamura@med.tohoku.ac.jp.
Yoh HamadaDepartment of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. yhamada@med.tohoku.ac.jp.
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. atihsayim8m8@med.tohoku.ac.jp.
Narumi Harada-ShojiDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. vecchio03@yahoo.co.jp.
Akiko SatoDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. aki_aki_tan@yahoo.co.jp.
Yohei HamanakaDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. h-y@med.tohoku.ac.jp.
Kouki TsuboiDepartment of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. k.tsuboi@med.tohoku.ac.jp.
Nobuhisa HaradaBio Systems Development Group, Bio Advanced Technology Division, Corporate R&D Headquarters, KONICA MINOLTA, INC., Hino, Tokyo 191-8511, Japan. nobuhisa.harada@konicaminolta.com.
Mayumi Takano-KasuyaDepartment of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. takano@med.tohoku.ac.jp.
Hisatake OkadaBio Systems Development Group, Bio Advanced Technology Division, Corporate R&D Headquarters, KONICA MINOLTA, INC., Hino, Tokyo 191-8511, Japan. hisatake.okada@konicaminolta.com.
Yasushi NakanoBio Systems Development Group, Bio Advanced Technology Division, Corporate R&D Headquarters, KONICA MINOLTA, INC., Hino, Tokyo 191-8511, Japan. yasushi.nakano@konicaminolta.com.
Noriaki OhuchiDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. noriaki-ohuchi@med.tohoku.ac.jp.
Shin-Ichi HayashiDepartment of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. shin@med.tohoku.ac.jp.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. takanori@med.tohoku.ac.jp.
Kohsuke GondaDepartment of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan. gonda@med.tohoku.ac.jp.
Tohoku University · JPKonica Minolta (Japan) · JP

Funding

China Scholarship Council 201608050086Japan Society for the Promotion of Science 16H05168Japan Society for the Promotion of Science 17K08972Japan Society for the Promotion of Science A3 Foresight Program
6 · The paper itself

Abstract

In addition to genomic signaling, Estrogen receptor alpha (ERα) is associated with cell proliferation and survival through extranuclear signaling contributing to endocrine therapy (ET) resistance. However, the relationship between extranuclear ERα and ET resistance has not been extensively studied. We sought to measure extranuclear ERα expression by immunohistochemistry using phosphor-integrated dots (IHC-PIDs) and to assess its predictive value for ET resistance. After quantitative detection of ERα by IHC-PIDs in vitro, we developed "the nearest-neighbor method" to calculate the extranuclear ERα. Furthermore, tissue sections from 65 patients with HR+/HER2- BC were examined by IHC-PIDs, and the total ERα, nuclear ERα, extranuclear ERα PIDs score, and ratio of extranuclear-to-nuclear ERα (ENR) were measured using the novel method. We demonstrate that quantification of ERα using IHC-PIDs exhibited strong correlations to real-time qRT-PCR (

Indexed as

breast cancerendocrine therapy resistanceestrogen receptor αIHC-PIDsprognostic

Identifiers

PMID31013810
PMCPMC6520781
OpenAlexW2939622275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.